24 February 2026 - The MHRA has today approved imlunestrant tosylate (Inluriyo), a new treatment for adult patients with a certain type of breast cancer that is locally advanced or has spread to other parts of the body (metastatic) and hasn’t responded, or has progressed further, following at least one line of hormonal treatment.

It is used when the cancer cells have oestrogen receptors and do not have many receptors called human epidermal growth factor receptor 2. Inluriyo can only be used in patients who have certain changes (mutations) in a gene called ESR1.

Read UK Government press release